Want to see UNCY full AI Analyst Report?
Total Valuation
Unicycive Therapeutics has a market cap or net worth of $153.48M. The enterprise value is $65.55.
Market Cap$153.48M
Enterprise Value$65.55
Share Statistics
Unicycive Therapeutics has 27,855,257 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,855,257
Owned by Insiders16.28%
Owned by Institutions20.41%
Financial Efficiency
Unicycive Therapeutics’s return on equity (ROE) is -0.88 and return on invested capital (ROIC) is -97.11%.
Return on Equity (ROE)-0.88
Return on Assets (ROA)-0.54
Return on Invested Capital (ROIC)-97.11%
Return on Capital Employed (ROCE)-0.98
Revenue Per Employee0.00
Profits Per Employee-1.26M
Employee Count21
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Unicycive Therapeutics is ―. Unicycive Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio0.00
PB Ratio3.04
Price to Fair Value3.04
Price to FCF-2.92
Price to Operating Cash Flow-5.33
PEG Ratio0.05
Income Statement
In the last 12 months, Unicycive Therapeutics had revenue of 0.00 and earned -26.55M in profits. Earnings per share was -1.67.
Revenue0.00
Gross Profit-572.00K
Operating Income-29.52M
Pretax Income-26.55M
Net Income-26.55M
EBITDA-25.91M
Earnings Per Share (EPS)-1.67
Cash Flow
In the last 12 months, operating cash flow was -27.84M and capital expenditures -9.00K, giving a free cash flow of -27.85M billion.
Operating Cash Flow-27.84M
Free Cash Flow-27.85M
Free Cash Flow per Share-1.00
Dividends & Yields
Unicycive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.45
52-Week Price Change35.05%
50-Day Moving Average5.97
200-Day Moving Average6.38
Relative Strength Index (RSI)51.90
Average Volume (3m)2.27M
Important Dates
Unicycive Therapeutics upcoming earnings date is Nov 18, 2026, Before Open (Confirmed).
Last Earnings DateAug 12, 2026
Next Earnings DateNov 18, 2026
Ex-Dividend Date―
Financial Position
Unicycive Therapeutics as a current ratio of 2.59, with Debt / Equity ratio of 1.26%
Current Ratio2.59
Quick Ratio2.59
Debt to Market Cap<0.01
Net Debt to EBITDA1.12
Interest Coverage Ratio-415.73
Taxes
In the past 12 months, Unicycive Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Unicycive Therapeutics EV to EBITDA ratio is -2.42, with an EV/FCF ratio of -2.00.
EV to Sales0.00
EV to EBITDA-2.42
EV to Free Cash Flow-2.00
EV to Operating Cash Flow-2.00
Balance Sheet
Unicycive Therapeutics has $61.42M in cash and marketable securities with $671.00K in debt, giving a net cash position of $60.75M billion.
Cash & Marketable Securities$61.42M
Total Debt$671.00K
Net Cash$60.75M
Net Cash Per Share$2.18
Tangible Book Value Per Share$1.90
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Unicycive Therapeutics is $34.71, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$34.71
Price Target Upside542.86% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast43.63%